New test may predict lung cancer treatment success
NCT ID NCT04589013
First seen Jan 06, 2026 · Last updated Jun 20, 2026 · Updated 28 times
Summary
This study tested whether a combination of 6 markers from tumor tissue could predict how well patients with advanced non-small cell lung cancer respond to first-line treatment with pembrolizumab (immunotherapy) plus chemotherapy. Researchers analyzed tissue samples from 106 patients before treatment and tracked disease progression or death over one year. The goal was to see if this multiparametric test outperforms the standard PD-L1 test alone in predicting outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CH Victor Provot
Roubaix, France
-
Clcc Oscar Lambret Lille
Lille, 59037, France
-
Clinique Teissier
Valenciennes, France
-
Hop Calmette Chu Lille
Lille, 59037, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this test could help doctors identify which lung cancer patients are most likely to benefit from immunotherapy combined with chemotherapy, avoiding ineffective treatments.
What could go wrong
This is a small, completed study that only looked at predicting outcomes, not changing treatment. The test may not be accurate enough for routine use and needs further validation.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.